Design of a Multi-Source Post-Marketing Study to Evaluate Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Who Were Exposed to Ocrelizumab During, or Within 6 Months Before, Pregnancy (P4.372)
Andrea V. Margulis, David Wormser(Novartis (Switzerland)), Sonia Hernández–Dı́az(Harvard University), Silvia Bader‐Weder(Roche (Switzerland)), Joanna Evershed(Roche (United Kingdom)), Elena Rivero‐Ferrer, Qīng Wáng(Beijing Technology and Business University), Elizabeth Andrews(University of California, Irvine), Monika Garas(Roche (Switzerland)), Melinda Magyari(University of Copenhagen)
Cited by 3
Related Papers
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
The Age-Specific Quantitative Effects of Metabolic Risk Factors on Cardiovascular Diseases and Diabetes: A Pooled Analysis
|PLoS ONE|2013|776
First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects
|New England Journal of Medicine|2007|497
The Birth Weight "Paradox" Uncovered?
|American Journal of Epidemiology|2006|359
Worldwide Incidence and Prevalence of Neuromyelitis Optica
|Neurology|2020|303